Coronavirus (COVID-19) News
Filter News
Found 1,376 articles
-
The U.S. appears to be beating back COVID-19 but it’s still raging in many parts of the world, and studies and trials are still ongoing. Here’s a look at some of today’s top COVID-19 stories.
-
The data may show the need for one, but vaccine and immunologists are pushing back against Pfizer and BioNTech’s contention that one is necessary now.
-
Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration
7/13/2021
Nascent Biotech, Inc., a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral infections, and its collaboration partner, Manhattan BioSolutions, are pleased to announce promising new preliminary preclinical results for the COVID-19 vaccine candidate now progressing under joint development by the Partners.
-
ZandCell COVID-19 vaccine order book grows to 160 million doses
7/13/2021
ZandCell, a biotech company with a proven track record in immunotherapies and COVID-19 diagnostics is announcing that it will enter into the manufacturing of COVID-19 vaccines for governments in need.
-
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial
7/13/2021
RELIEF THERAPEUTICS Holding AG, NRx Pharmaceuticals, Inc., and Quantum Leap Healthcare Collaborative have announced that they have begun treating patients with inhaled aviptadil in the I-SPY COVID Trial, a phase 2 adaptive platform trial aimed at improving treatment for severely and critically ill COVID-19 patients.
-
Statement from the Chief Public Health Officer of Canada on July 13, 2021
7/13/2021
The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.
-
Canadian researchers to study best approaches to possible adverse events following COVID-19 vaccination
7/13/2021
The Government of Canada, through its COVID-19 Immunity Task Force and Vaccine Surveillance Reference Group, is investing approximately $800,000 for a study that aims to further improve Canada’s identification and response to adverse events people may experience following COVID-19 vaccination across 10 provinces.
-
Approximately 100 preliminary reports of GBS have been identified out of 12.8 million doses of the J&J vaccine in the U.S., according to the Centers for Disease Control and Prevention.
-
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
-
HHS issued their announcement, saying, “Americans who have been fully vaccinated do not need a booster shot at this time.”
-
Clinical Catch-Up: July 5-9
7/12/2021
Last week presented a fair number of clinical trial news. Read on for more information. -
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
7/12/2021
SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that it had signed an advance purchase agreement with Gavi, the Vaccine Alliance, which is on behalf of COVAX Facility, to provide up to 380 million doses of inactivated COVID-19 vaccine, CoronaVac®for distribution through the COVAX Facility.
-
Inotrem Receives Approval to Expand Nangibotide Clinical Trial in Critically Ill COVID-19 Patients and Receives Additional Public Funding of €45 Million
7/12/2021
Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in COVID-19 patients from both the French and Belgian competent authorities.
-
Government of Canada funds five new projects to encourage COVID-19 vaccination in Canada
7/12/2021
The Honourable Patty Hajdu, Minister of Health, announced five new projects receiving funding through the Immunization Partnership Fund to support vaccination efforts across Canada.
-
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
7/12/2021
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials of molnupiravir, an investigational oral antiviral therapeutic.
-
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
7/12/2021
Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19 announces new positive preclinical data on Sarconeos in hamsters infected with SARS-CoV-2.
-
The two companies said a booster dose given six months after the second dose had a consistent tolerability profile while still creating high immune responses against the Alpha and Beta variant.
-
Sinovac’s CoronaVac was the first COVID-19 vaccine approved in China for emergency use back in June 2020.
-
The vaccine demonstrated efficacy in mild, moderate, and severe COVID-19 of 77.8% with efficacy against severe disease of 93.4%.
-
Ivermectin has become a contentious issue as to whether it effectively prevents and treats COVID-19. Several studies suggest it is effective, while others have indicated it is not.